z-logo
open-access-imgOpen Access
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells
Author(s) -
Bo Song,
Yuan Wang,
Yaguang Xi,
Kenji Kudo,
Skjalg Bruheim,
Galina I. Botchkina,
Elaine Gavin,
Yu Wan,
A. Formentini,
Marko Kornmann,
Øystein Fodstad,
Jingfang Ju
Publication year - 2009
Publication title -
oncogene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.395
H-Index - 342
eISSN - 1476-5594
pISSN - 0950-9232
DOI - 10.1038/onc.2009.274
Subject(s) - biology , cancer research , osteosarcoma , microrna , cell cycle , cell growth , cell culture , cd44 , transfection , colorectal cancer , cancer , cancer cell , cancer stem cell , null cell , carcinogenesis , cell , genetics , gene
In this study, high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts. Tumor cells ectopically transfected with miR-140 were more resistant to methotrexate and 5-fluorouracil (5-FU). Overexpression of miR-140 inhibited cell proliferation in both osteosarcoma U-2 OS (wt-p53) and colon cancer HCT 116 (wt-p53) cell lines, but less so in osteosarcoma MG63 (mut-p53) and colon cancer HCT 116 (null-p53) cell lines. miR-140 induced p53 and p21 expression accompanied with G(1) and G(2) phase arrest only in cell lines containing wild type of p53. Histone deacetylase 4 (HDAC4) was confirmed to be one of the important targets of miR-140. The expression of endogenous miR-140 was significantly elevated in CD133(+hi)CD44(+hi) colon cancer stem-like cells that exhibit slow proliferating rate and chemoresistance. Blocking endogenous miR-140 by locked nucleic acid-modified anti-miR partially sensitized resistant colon cancer stem-like cells to 5-FU treatment. Taken together, our findings indicate that miR-140 is involved in the chemoresistance by reduced cell proliferation through G(1) and G(2) phase arrest mediated in part through the suppression of HDAC4. miR-140 may be a candidate target to develop novel therapeutic strategy to overcome drug resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here